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● Electronic vaping associated lung injury (EVALI), is an acute or subacute respiratory
illness that can be severe and life-threatening. This clinical vignette hopes to
provide a reference for initial identification, treatment and management.
● As of February 18, 2020, a total of 2,807 hospitalized EVALI cases or deaths have
been reported to CDC from 50 states, the District of Columbia, and two U.S.
territories (Puerto Rico and U.S. Virgin Islands).1
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● The key risk factor for EVALI is use of an e-cigarette or similar products.1,2 Ecigarette, or vaping, products have evolved into a diverse class of inhaled aerosol
devices. The U.S. markets for both nicotine- and THC-containing vaping products
have dramatically expanded. There has been an increase in the use of nicotinecontaining products by young people. Simultaneously, an increasing number of U.S.
states have legalized marijuana use.
● In 2019, more than 5.2 million young people in the United States reported current
use, including 27.5% of high school students and 10.5% of middle school
students.3,4 In contrast, current use among adults remained unchanged from 2014
to 2017, and in 2018, 3.2% of U.S. adults (8.1 million) reported current use of ecigarettes, including 7.6% of adults 18 to 24 years of age (2.1 million).4,5
● Use of these products among young people is driven by multiple factors, including
advertising, attractive flavors, and the availability of easily concealable devices that
deliver high levels of nicotine.6

Figure 1. Dates of symptom onset and hospital admission for patients
with EVALI- United States, March 31, 2019-February 15,20201

Case Presentation
Patient is a 21-year-old male without significant past medical history who presented
with increased shortness of breath and dry cough with pleuritic chest pain. The cough
was progressive, leading to post-tussive emesis. The patient admits to a 7-month daily
vaping history with marijuana and nicotine.
In the ER, temperature was 102.7oF, pulse 141, blood pressure 117/56, respiratory
rate 35 and an O2 saturation of 60%. He received methylprednisolone 125 mg,
albuterol/ipratropium treatment, acetaminophen 1000 mg, and ceftriaxone 1 g. Chest
x-ray (CXR) and CT showed dense reticular nodular parenchymal opacities involving
all lobes of bilateral lungs. There was a combination of ground-glass with
superimposed central lobular and interlobular septal thickening. Drug screen was
positive for THC. His arterial blood gas in the ED revealed: pH 7.44, pO2 96, pCO2
35.2, bicarb 23.9 on 8 liters of oxygen via nasal cannula.
Patient was admitted to the ICU and placed on high flow nasal cannula due to
worsening hypoxia. He was started on scheduled bronchodilators, steroids and empiric
antibiotic coverage with ceftriaxone, vancomycin and azithromycin. A viral respiratory
panel and HIV testing were negative. Mycoplasma IgM antibody was positive, although
specificity is known to be poor. Ceftriaxone and vancomycin were stopped and he
completed a 3 day course of azithromycin 500 mg daily. He was then started on IV
steroids 60 mg q8 hours, tapered over 10 days, while being weaned off oxygen.

Figure 8. Percentage of middle and high school students who currently use e-cigarettes
and any tobacco product— National Youth Tobacco Survey, United States, 2011–2018
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Conclusion

Figure 6. Posterior coronal section.

Figure 7. Inferior transverse section

Figure 2-7 show Chest CT of the patient with EVALI. Dense reticulonodular
parenchymal opacities involving all lobes of both lungs. High-resolution scanning
demonstrates a combination of ground glass opacity with superimposed interlobular
and intralobular septal thickening

● With this case, our hope is to provide a clinical example of successful screening and
treatment of EVALI. Practitioners should screen for other infectious entities that
may be exacerbated by steroid therapy.7,8
● Patients discharged from the hospital after inpatient treatment for EVALI should
have a follow-up visit within 1–2 weeks. The follow-up evaluation should include
pulse-oximetry and consideration of a repeat CXR.
● Additional follow-up testing 1–2 months after discharge might include spirometry,
diffusion capacity for carbon monoxide, and CXR.9
● Long-term effects and the risk for recurrence of EVALI are not known and will
require further progressive studies.
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